{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-095317","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2023-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.686172+00:00","generated_at":"2026-06-17T04:47:26.264232+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"TherapeuticsMD posts $1.1M net income from continuing ops in FY2022 vs loss of $79.3M in 2021","bullets":["License revenue surged to $70.0M from $2.6M, driven by $140M upfront from Mayne Pharma transaction.","Company repaid all $188.3M debt, redeemed Series A preferred stock, and has $38.1M cash on hand.","Discontinued ops generated $80.7M product revenue; net income of $110.9M vs loss in 2021.","Reduced to one full-time employee; transition to virtual royalty model from Mayne Pharma license.","Eligible for up to $30M milestones and 7.5%-8% royalties for 20 years with $3M minimum annual royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-095317","json":"https://secwatch.observer/filing/0001193125-23-095317.json","markdown":"https://secwatch.observer/filing/0001193125-23-095317.md","text":"https://secwatch.observer/filing/0001193125-23-095317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000119312523095317/0001193125-23-095317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000119312523095317/d485631d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T04:47:26.264232+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"48f914825ce031279c102774d42fe435a2a65de7","claim":"TherapeuticsMD, Inc. reported the full year ended December 31, 2022 results: revenue $70.0 million, net income $1.1 million, EPS $0.12 per basic share.","evidence_excerpt":"License Revenues from Continuing Operations • License revenues from continuing operations, which are revenues from continuing operations related to license agreements, were $70.0 million for the year ended December 31, 2022, compared to $2.6 million for 2021. The increase in license revenues was a result of the allocation of the initial upfront payment and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000119312523095317/0001193125-23-095317-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Revenue","value":"$70.0 million"},{"label":"Net income","value":"$1.1 million"},{"label":"EPS","value":"$0.12 per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}